Apogee Therapeutics, Inc. (APGE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put APGE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is volatile — it swings about 0% on a typical day and fell roughly 25% in its worst 12-month stretch.
View RiskAPGE's growth depends on the successful completion of its acquisition by AbbVie. Revenue performance has been weak, with the latest earnings report missing expectations. The stock trades at a valuation that appears roughly in line with its growth potential. Analysts have noted a 37% probability of missing expectations in the next quarter. If APGE cuts guidance or if sector bellwethers start missing earnings, the stock could face downward pressure. Peer multiples imply a price roughly in line with where it trades (about fair); our read is provisional.
Trailing returns as of 2026-09-02. APGE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering APGE (as of Sep 2026).
Based on 9 Wall Street analysts offering 12-month price targets for APGE in the last 4 months.
Continue this research
Compare APGE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| APGE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put APGE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete acquisition by AbbVie
Financing supports acquisition, enhancing strategic alignment.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-02. EPS is implied from price ÷ P/E. Not investment advice.
Current $135.07
The last 12 months of price, then the range of analyst 12-month targets from today’s $135.07.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Begin Phase 3 trials of zumilokibart
Phase 3 trials for zumilokibart are a key objective.
Advances: Begin Phase 3 trials of zumilokibart
Progress on pivotal trial for eczema supports product development.
CEO stock sale raises concerns about insider confidence.
Advances: Begin Phase 3 trials of zumilokibart
Positive trial outlook boosts confidence in Phase 3.